<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="osp470064" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Obes Sci Pract</journal-id><journal-id journal-id-type="iso-abbrev">Obes Sci Pract</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2055-2238</journal-id><journal-id journal-id-type="publisher-id">OSP4</journal-id><journal-title-group><journal-title>Obesity Science &#x00026; Practice</journal-title></journal-title-group><issn pub-type="epub">2055-2238</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11864105</article-id><article-id pub-id-type="doi">10.1002/osp4.70064</article-id><article-id pub-id-type="publisher-id">OSP470064</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Pancreatic &#x003b2;&#x02010;cell Function is Higher in Morning Versus Intermediate Chronotypes With Obesity</article-title></title-group><contrib-group><contrib id="osp470064-cr-0001" contrib-type="author" corresp="yes"><name><surname>Malin</surname><given-names>Steven K.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7360-6711</contrib-id><xref rid="osp470064-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="osp470064-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="osp470064-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="osp470064-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><address><email>steven.malin@rutgers.edu</email></address></contrib><contrib id="osp470064-cr-0002" contrib-type="author"><name><surname>Remchak</surname><given-names>Mary&#x02010;Margaret E.</given-names></name><xref rid="osp470064-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="osp470064-cr-0003" contrib-type="author"><name><surname>Heiston</surname><given-names>Emily M.</given-names></name><xref rid="osp470064-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="osp470064-cr-0004" contrib-type="author"><name><surname>Fabris</surname><given-names>Chiara</given-names></name><xref rid="osp470064-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="osp470064-cr-0005" contrib-type="author"><name><surname>Shah</surname><given-names>Ankit M.</given-names></name><xref rid="osp470064-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="osp470064-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Kinesiology &#x00026; Health</named-content>
<institution>Rutgers University</institution>
<city>New Brunswick</city>
<named-content content-type="country-part">New Jersey</named-content>
<country country="US">USA</country>
</aff><aff id="osp470064-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Division of Endocrinology, Metabolism &#x00026; Nutrition</named-content>
<institution>Rutgers University</institution>
<city>New Brunswick</city>
<named-content content-type="country-part">New Jersey</named-content>
<country country="US">USA</country>
</aff><aff content-type="private-address" id="osp470064-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>New Jersey Institute for Food</institution>
<institution>Nutrition and Health</institution>
<institution>Rutgers University</institution>
<city>New Brunswick</city>
<named-content content-type="country-part">New Jersey</named-content>
<country country="US">USA</country>
</aff><aff content-type="private-address" id="osp470064-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Institute of Translational Medicine and Science</institution>
<institution>Rutgers University</institution>
<city>New Brunswick</city>
<named-content content-type="country-part">New Jersey</named-content>
<country country="US">USA</country>
</aff><aff content-type="private-address" id="osp470064-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>Center for Diabetes Technology</institution>
<institution>School of Medicine</institution>
<institution>University of Virginia</institution>
<city>Charlottesville</city>
<named-content content-type="country-part">Virginia</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold> Steven K. Malin<break/>
(<email>steven.malin@rutgers.edu</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>11</volume><issue seq="20">2</issue><issue-id pub-id-type="doi">10.1002/osp4.v11.2</issue-id><elocation-id>e70064</elocation-id><history>
<date date-type="rev-recd"><day>07</day><month>2</month><year>2025</year></date>
<date date-type="received"><day>04</day><month>12</month><year>2024</year></date>
<date date-type="accepted"><day>14</day><month>2</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 The Author(s). Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Obesity Science &#x00026; Practice</italic> published by World Obesity and The Obesity Society and John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:OSP4-11-e70064.pdf"/><abstract><title>ABSTRACT</title><sec id="osp470064-sec-0001"><title>Objectives</title><p>People with later chronotypes are at greater T2D risk, yet it is unknown if &#x003b2;&#x02010;cell function differs among chronotypes. Thus we, assessed &#x003b2;&#x02010;cell function in morning (MORN) and intermediate (INT) chronotypes with obesity.</p></sec><sec id="osp470064-sec-0002"><title>Methods</title><p>Adults (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;41, 9M, 55&#x000a0;&#x000b1;&#x000a0;1.7&#x000a0;y, 36.8&#x000a0;&#x000b1;&#x000a0;1.0&#x000a0;kg/m<sup>2</sup>) were grouped as MORN or INT per the Morningness&#x02010;Eveningness Questionnaire. Glucose, insulin, C&#x02010;peptide, GIP, and GLP&#x02010;1(active) were collected every 30&#x000a0;min during a 120&#x000a0;min 75g&#x02010;OGTT. Insulin secretion rates (ISR) were calculated (regularized deconvolution) to assess early (total area under the curve; tAUC<sub>0&#x02013;30min</sub>) and total&#x02010;phase (tAUC<sub>0&#x02013;120min</sub>) glucose&#x02010;stimulated insulin secretion (GSIS:ISR/Glucose). Skeletal muscle (glucose infusion rate/steady&#x02010;state insulin) insulin sensitivity and hepatic (HOMA&#x02010;IR) as well as adipose (Adipose&#x02010;IR) insulin resistance were assessed during a 120&#x000a0;min euglycemic hyperinsulinemic clamp (40mU/m<sup>2</sup>/min, 90&#x000a0;mg/dL). &#x003b2;&#x02010;cell function (disposition index (DI): GSIS adjusted insulin sensitivity) was determined. Body composition (DXA) and fitness (VO<sub>2</sub>max) were also measured.</p></sec><sec id="osp470064-sec-0003"><title>Results</title><p>Age, body composition and VO<sub>2</sub>max were similar between groups, but INT had reduced muscle insulin sensitivity and higher hepatic and adipose IR (<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05). INT had higher C&#x02010;peptide tAUC<sub>0&#x02013;30min</sub> (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.04) and lower hepatic DI (tAUC<sub>0&#x02013;30min</sub>
<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.05 and tAUC<sub>0&#x02013;120min</sub>
<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.07, respectively). Early phase hepatic DI correlated with GLP&#x02010;1 tAUC<sub>0&#x02013;30min</sub> (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.35, <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.02) and tAUC<sub>0&#x02013;120min</sub> (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;&#x02212;0.40, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.04).</p></sec><sec id="osp470064-sec-0004"><title>Conclusions</title><p>&#x003b2;&#x02010;cell function was higher in MORN versus INT chronotypes. Further work is warranted to discern how chronotype impacts insulin secretion.</p></sec><sec id="osp470064-sec-0005"><title>Trial Registration</title><p>NCT03355469</p></sec></abstract><kwd-group><kwd id="osp470064-kwd-0001">glycemic control</kwd><kwd id="osp470064-kwd-0002">incretins</kwd><kwd id="osp470064-kwd-0003">insulin resistance</kwd><kwd id="osp470064-kwd-0004">insulin secretion</kwd><kwd id="osp470064-kwd-0005">type 2 diabetes</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>National Heart, Lung, and Blood Institute</funding-source><award-id>RO1&#x02010;HL130296</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="3"/><page-count count="10"/><word-count count="6263"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:26.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="osp470064-note-0001"><p>
<bold>Funding:</bold> Work supported by National Institutes of Health RO1&#x02010;HL130296 (SKM).</p></fn></fn-group></notes></front><body id="osp470064-body-0001"><sec id="osp470064-sec-0010"><label>1</label><title>Introduction</title><p>Chronotype reflects the behavioral and physiologic processes that influence preference to engage in lifestyle behaviors across the day. Specifically, those with evening chronotypes (i.e. &#x0201c;night owls&#x0201d;) prefer to wake up and/or engage in activity later in the day compared with those with morning chronotypes (i.e. &#x0201c;early bird&#x0201d;) who engage in most acts of living during the morning hours. People with intermediate chronotypes tend to engage in activities during both early and later portions of the day. Evening chronotypes have a higher risk of type 2 diabetes than morning or intermediate chronotypes due to, in part, insulin resistance [<xref rid="osp470064-bib-0001" ref-type="bibr">1</xref>, <xref rid="osp470064-bib-0002" ref-type="bibr">2</xref>]. Interestingly, the central clock (e.g. suprachiasmatic nucleus) regulates whole&#x02010;body insulin sensitivity through in part neural input, while peripheral clocks in muscle, adipose and liver determine tissue specific insulin action [<xref rid="osp470064-bib-0003" ref-type="bibr">3</xref>]. However, improving &#x003b2;&#x02010;cell function to secrete insulin relative to low skeletal muscle, liver and/or adipose insulin sensitivity is critical to promote glycemic control [<xref rid="osp470064-bib-0004" ref-type="bibr">4</xref>]. In this regard, focus on pancreatic function warrants attention for the regulation of insulin secretion since misalignment between daily rhythms of sleep, eating, or movement may raise the risk of type 2 diabetes.</p><p>Glucose tolerance is typically higher in the morning than in the evening among healthy people [<xref rid="osp470064-bib-0005" ref-type="bibr">5</xref>, <xref rid="osp470064-bib-0006" ref-type="bibr">6</xref>], and this time of day dependent effect is primarily driven by declines in pancreatic &#x003b2;&#x02010;cell responses to nutrients [<xref rid="osp470064-bib-0007" ref-type="bibr">7</xref>, <xref rid="osp470064-bib-0008" ref-type="bibr">8</xref>, <xref rid="osp470064-bib-0009" ref-type="bibr">9</xref>]. Rodent [<xref rid="osp470064-bib-0010" ref-type="bibr">10</xref>] and human pancreatic islet studies [<xref rid="osp470064-bib-0011" ref-type="bibr">11</xref>] demonstrate that the transcription factors CLOCK and BMAL1 activate gene expression that regulates insulin biosynthesis, transport and glucose&#x02010;stimulated insulin secretion [<xref rid="osp470064-bib-0012" ref-type="bibr">12</xref>]. Despite work suggesting pancreatic &#x003b2;&#x02010;cells are under circadian system regulation and people with obesity/type 2 diabetes have blunted diurnal patterns [<xref rid="osp470064-bib-0008" ref-type="bibr">8</xref>, <xref rid="osp470064-bib-0009" ref-type="bibr">9</xref>, <xref rid="osp470064-bib-0013" ref-type="bibr">13</xref>, <xref rid="osp470064-bib-0014" ref-type="bibr">14</xref>], no work has been done to examine glucose&#x02010;stimulated insulin secretion and pancreatic function in people with different chronotypes. This limits insight into how the &#x003b2;&#x02010;cell responds to glucose via the triggering pathway for insulin secretion as well as if incretin hormones that act on amplifying pathways of the &#x003b2;&#x02010;cell, such as GLP&#x02010;1 (glucagon&#x02010;like polypeptide&#x02010;1) and/or GIP (glucose insulinotropic polypeptide), differ among chronotypes [<xref rid="osp470064-bib-0015" ref-type="bibr">15</xref>]. Previously, it was shown using the euglycemic&#x02010;clamp and ultrasound approaches that people with early chronotypes have higher metabolic insulin sensitivity compared with people with later chronotypes, and those with morning chronotype have more favorable insulin&#x02010;stimulated endothelial function than those with intermediate chronotypes [<xref rid="osp470064-bib-0002" ref-type="bibr">2</xref>, <xref rid="osp470064-bib-0016" ref-type="bibr">16</xref>]. Subsequently, it would be reasonable to anticipate that people with intermediate chronotypes (INT) would have lower pancreatic &#x003b2;&#x02010;cell function compared with morning (MORN) chronotypes. This is important because people with obesity have reduced early and late phase insulin secretion, thereby raising the risk of type 2 diabetes [<xref rid="osp470064-bib-0017" ref-type="bibr">17</xref>]. Thus, attention to INT has public health significance as nearly 50% of the population identifies within this classification [<xref rid="osp470064-bib-0018" ref-type="bibr">18</xref>]. The purpose of this study was to determine if people with MORN and INT would differ in early and total phase &#x003b2;&#x02010;cell function. It was hypothesized that people with the MORN chronotype would have different &#x003b2;&#x02010;cell functions than those with INT chronotype, and this would relate to the incretins GLP&#x02010;1 and GIP.</p></sec><sec id="osp470064-sec-0020"><label>2</label><title>Methods</title><sec id="osp470064-sec-0030"><label>2.1</label><title>Participants</title><p>Sedentary individuals were enrolled in this cross&#x02010;sectional study. People with obesity were recruited by flyers, social media, and/or electronic medical records from the local communities. To classify participants as either MORN or INT, we used the Morningness&#x02010;Eveningness Questionnaire (MEQ) as previously described [<xref rid="osp470064-bib-0002" ref-type="bibr">2</xref>] from participants with available plasma for C&#x02010;peptides (Table&#x000a0;<xref rid="osp470064-tbl-0001" ref-type="table">1</xref>). The Epworth Sleepiness Scale was used to assess the likelihood of falling asleep during specific daily events (i.e. watching tv, sitting inactive, in a car while stopped, etc.), and the Pittsburgh Sleep Quality Index (PSQI) was used to assess quality and patterns of sleep [<xref rid="osp470064-bib-0019" ref-type="bibr">19</xref>, <xref rid="osp470064-bib-0020" ref-type="bibr">20</xref>]. Participants underwent a physical exam prior to exercise testing that included an overnight 12&#x000a0;h fasted blood/urine chemistries (e.g. liver enzymes (alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine transaminase (ALT)), HbA1c, total triglycerides, total cholesterol, VLDL cholesterol, LDL cholesterol, and HDL cholesterol) and resting electrocardiogram (ECG). Blood pressure was also determined. Participants were excluded from the study if they were physically active (exercise &#x0003e; 1&#x000a0;h/wk) [<xref rid="osp470064-bib-0021" ref-type="bibr">21</xref>], smoked, weight unstable (&#x0003e; 2&#x000a0;kg weight change during last 3&#x000a0;months), diagnosed with type 2 diabetes, or currently taking medications known to influence insulin sensitivity or endothelial function (e.g., biguanides, calcium channel blockers, &#x003b1;&#x02010;blockers, &#x003b2;&#x02010;blockers, etc.). Female participants were asked to indicate menses status (e.g. menopause; Table&#x000a0;<xref rid="osp470064-tbl-0001" ref-type="table">1</xref>). Women were not on oral contraceptives, nor did any report use of hormone replacement treatment. Participants provided both written and verbal informed consent as approved by the Institutional Review Board. This study was part of a larger clinical trial (Registration # NCT03355469).</p><table-wrap position="float" id="osp470064-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Morning and intermediate chronotype characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">MORN</th><th align="center" valign="bottom" rowspan="1" colspan="1">INT</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cohen's <italic toggle="yes">d</italic> effect size</th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" rowspan="1">Participant demographics</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">N (F)</td><td align="center" valign="top" rowspan="1" colspan="1">25 (21F)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (11F)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Age (yrs)</td><td align="center" valign="top" rowspan="1" colspan="1">52.4&#x000a0;&#x000b1;&#x000a0;1.2</td><td align="center" valign="top" rowspan="1" colspan="1">53.3&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.68</td><td align="center" valign="top" rowspan="1" colspan="1">0.13</td></tr><tr><td colspan="5" style="padding-left:10%" align="left" valign="top" rowspan="1">Menopausal status (%)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Pre</td><td align="center" valign="top" rowspan="1" colspan="1">44</td><td align="center" valign="top" rowspan="1" colspan="1">50</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Peri</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Post</td><td align="center" valign="top" rowspan="1" colspan="1">44</td><td align="center" valign="top" rowspan="1" colspan="1">38</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" style="padding-left:10%" align="left" valign="top" rowspan="1">Race/Ethnicity</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">African American</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Hispanic/Latino</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">22</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">MEQ score</td><td align="center" valign="top" rowspan="1" colspan="1">63.6&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="center" valign="top" rowspan="1" colspan="1">51.7&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x000a0;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.59</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Epworth sleep score</td><td align="center" valign="top" rowspan="1" colspan="1">6.7&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">6.7&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.95</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PSQI</td><td align="center" valign="top" rowspan="1" colspan="1">5.7&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="center" valign="top" rowspan="1" colspan="1">7.5&#x000a0;&#x000b1;&#x000a0;1.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.22</td><td align="center" valign="top" rowspan="1" colspan="1">0.48</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">3&#x02010;Factor sleep efficiency</td><td align="center" valign="top" rowspan="1" colspan="1">1.3&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="center" valign="top" rowspan="1" colspan="1">1.5&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.66</td><td align="center" valign="top" rowspan="1" colspan="1">0.15</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">3&#x02010;Factor sleep quality</td><td align="center" valign="top" rowspan="1" colspan="1">2.2&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="center" valign="top" rowspan="1" colspan="1">3.2&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.26</td><td align="center" valign="top" rowspan="1" colspan="1">0.39</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">3&#x02010;Factor daily disturbances</td><td align="center" valign="top" rowspan="1" colspan="1">2.2&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">2.6&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.20</td><td align="center" valign="top" rowspan="1" colspan="1">0.42</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Body Mass and composition</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Weight (kg)</td><td align="center" valign="top" rowspan="1" colspan="1">101.8&#x000a0;&#x000b1;&#x000a0;3.4</td><td align="center" valign="top" rowspan="1" colspan="1">105.2&#x000a0;&#x000b1;&#x000a0;5.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.58</td><td align="center" valign="top" rowspan="1" colspan="1">0.18</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">36.4&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">36.7&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.85</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">WC (cm)</td><td align="center" valign="top" rowspan="1" colspan="1">111.2&#x000a0;&#x000b1;&#x000a0;2.1</td><td align="center" valign="top" rowspan="1" colspan="1">115.6&#x000a0;&#x000b1;&#x000a0;3.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.30</td><td align="center" valign="top" rowspan="1" colspan="1">0.36</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Body fat (%)</td><td align="center" valign="top" rowspan="1" colspan="1">43.9&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="center" valign="top" rowspan="1" colspan="1">44.0&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.92</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fat Mass (kg)</td><td align="center" valign="top" rowspan="1" colspan="1">42.8&#x000a0;&#x000b1;&#x000a0;1.9</td><td align="center" valign="top" rowspan="1" colspan="1">44.2&#x000a0;&#x000b1;&#x000a0;2.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.67</td><td align="center" valign="top" rowspan="1" colspan="1">0.15</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">VAT (cm<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">1161.5&#x000a0;&#x000b1;&#x000a0;122.4</td><td align="center" valign="top" rowspan="1" colspan="1">1025.3&#x000a0;&#x000b1;&#x000a0;88.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.37</td><td align="center" valign="top" rowspan="1" colspan="1">0.27</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Sub&#x02010;Q (kg)</td><td align="center" valign="top" rowspan="1" colspan="1">2.8&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="center" valign="top" rowspan="1" colspan="1">3.4&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.54</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">LBM (kg)</td><td align="center" valign="top" rowspan="1" colspan="1">52.3&#x000a0;&#x000b1;&#x000a0;1.9</td><td align="center" valign="top" rowspan="1" colspan="1">55.1&#x000a0;&#x000b1;&#x000a0;3.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.51</td><td align="center" valign="top" rowspan="1" colspan="1">0.25</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Fitness, blood pressure, and clinical labs</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">VO<sub>2</sub>max (mL/kg/min)</td><td align="center" valign="top" rowspan="1" colspan="1">23.4&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="center" valign="top" rowspan="1" colspan="1">22.2&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.34</td><td align="center" valign="top" rowspan="1" colspan="1">0.29</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" valign="top" rowspan="1" colspan="1">130.1&#x000a0;&#x000b1;&#x000a0;2.8</td><td align="center" valign="top" rowspan="1" colspan="1">135.8&#x000a0;&#x000b1;&#x000a0;2.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.13</td><td align="center" valign="top" rowspan="1" colspan="1">0.44</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" valign="top" rowspan="1" colspan="1">77.8&#x000a0;&#x000b1;&#x000a0;1.9</td><td align="center" valign="top" rowspan="1" colspan="1">81.1&#x000a0;&#x000b1;&#x000a0;2.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.30</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HbA1c (%)</td><td align="center" valign="top" rowspan="1" colspan="1">5.7&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="center" valign="top" rowspan="1" colspan="1">5.5&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.45</td><td align="center" valign="top" rowspan="1" colspan="1">0.29</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">TG (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">152.1&#x000a0;&#x000b1;&#x000a0;15.4</td><td align="center" valign="top" rowspan="1" colspan="1">170.0&#x000a0;&#x000b1;&#x000a0;16.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.45</td><td align="center" valign="top" rowspan="1" colspan="1">0.24</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Total cholesterol (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">207.8&#x000a0;&#x000b1;&#x000a0;6.7</td><td align="center" valign="top" rowspan="1" colspan="1">225.3&#x000a0;&#x000b1;&#x000a0;12.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.44</td><td align="center" valign="top" rowspan="1" colspan="1">0.43</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HDL (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">45.6&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="center" valign="top" rowspan="1" colspan="1">48.0&#x000a0;&#x000b1;&#x000a0;2.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.40</td><td align="center" valign="top" rowspan="1" colspan="1">0.26</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">TG:HDL ratio</td><td align="center" valign="top" rowspan="1" colspan="1">3.5&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" valign="top" rowspan="1" colspan="1">3.7&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.77</td><td align="center" valign="top" rowspan="1" colspan="1">0.09</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">LDL (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">135.9&#x000a0;&#x000b1;&#x000a0;5.0</td><td align="center" valign="top" rowspan="1" colspan="1">148.7&#x000a0;&#x000b1;&#x000a0;10.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.28</td><td align="center" valign="top" rowspan="1" colspan="1">0.38</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">AST (U/L)</td><td align="center" valign="top" rowspan="1" colspan="1">22.9&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="center" valign="top" rowspan="1" colspan="1">28.0&#x000a0;&#x000b1;&#x000a0;2.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.67</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ALT (U/L)</td><td align="center" valign="top" rowspan="1" colspan="1">28.1&#x000a0;&#x000b1;&#x000a0;3.7</td><td align="center" valign="top" rowspan="1" colspan="1">35.8&#x000a0;&#x000b1;&#x000a0;3.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.13</td><td align="center" valign="top" rowspan="1" colspan="1">0.45</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ALP (U/L)</td><td align="center" valign="top" rowspan="1" colspan="1">68.5&#x000a0;&#x000b1;&#x000a0;4.1</td><td align="center" valign="top" rowspan="1" colspan="1">68.5&#x000a0;&#x000b1;&#x000a0;4.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.39</td></tr></tbody></table><table-wrap-foot id="osp470064-ntgp-0001"><fn id="osp470064-note-0002"><p>
<italic toggle="yes">Note:</italic> Data are expressed as mean&#x000a0;&#x000b1;&#x000a0;SEM.</p></fn><fn id="osp470064-note-0003"><p>Abbreviations: ALP&#x000a0;=&#x000a0;alkaline phosphatase; ALT&#x000a0;=&#x000a0;alanine aminotransferase; AST&#x000a0;=&#x000a0;aspartate aminotransferase; BMI&#x000a0;=&#x000a0;body mass index; DBP&#x000a0;=&#x000a0;diastolic blood pressure; HbA1c&#x000a0;=&#x000a0;hemoglobin A1c; HDL&#x000a0;=&#x000a0;high density lipoprotein; INT&#x000a0;=&#x000a0;intermediate chronotype; LBM&#x000a0;=&#x000a0;lean body mass; LDL&#x000a0;=&#x000a0;low density lipoprotein; MEQ&#x000a0;=&#x000a0;morning eveningness questionnaire; MORN&#x000a0;=&#x000a0;morning chronotype; PSQI = Pittsburgh sleep quality index; SBP&#x000a0;=&#x000a0;systolic blood pressure; SubQ&#x000a0;=&#x000a0;subcutaneous fat; TG&#x000a0;=&#x000a0;triglycerides; VAT&#x000a0;=&#x000a0;visceral fat; VO<sub>2</sub>max&#x000a0;=&#x000a0;maximal oxygen consumption.</p></fn></table-wrap-foot></table-wrap></sec><sec id="osp470064-sec-0040"><label>2.2</label><title>Cardiorespiratory Fitness</title><p>Maximal oxygen consumption (VO<sub>2</sub>max) was used to determine cardiorespiratory fitness and was tested on a treadmill with indirect calorimetry. Individuals were asked to self&#x02010;select a speed and the incline was elevated every 2&#x000a0;min until exhaustion as described before [<xref rid="osp470064-bib-0022" ref-type="bibr">22</xref>].</p></sec><sec id="osp470064-sec-0050"><label>2.3</label><title>Body Composition</title><p>A digital scale was used to assess body weight to the nearest 0.10&#x000a0;kg while participants wore minimal clothing and no shoes. Height was assessed to the nearest 0.10&#x000a0;cm using a stadiometer to ultimately calculate body mass index (BMI). Total body fat and lean body mass (LBM) were measured using dual&#x02010;energy X&#x02010;ray absorptiometry (Horizon DXA System, Marlborough, MA). Waist circumference (WC) was defined 2&#x000a0;cm above the umbilicus. WC was obtained twice and averaged using a tape measure to the nearest 0.10&#x000a0;cm.</p></sec><sec id="osp470064-sec-0060"><label>2.4</label><title>Metabolic Control</title><p>A diet consisting of 55% carbohydrates, 15% protein, and 30% fat, with &#x0003c; 10% from saturated fat, was provided to standardize food consumption 24&#x000a0;h prior to the clamp and oral glucose tolerance test (OGTT). Food intake need was based on fasted resting metabolic rate (RMR) derived from indirect calorimetry, which was multiplied by a physical activity factor of 1.2. Individuals were also asked to avoid medication, caffeine, alcohol and engagement in moderate to vigorous physical activity 24&#x000a0;h prior to the study visits.</p></sec><sec id="osp470064-sec-0070"><label>2.5</label><title>Euglycemic Clamp</title><p>After an overnight fast of about 10&#x000a0;h, participants arrived at the Clinical Research Center (CRC) as described previously [<xref rid="osp470064-bib-0023" ref-type="bibr">23</xref>]. A catheter was placed in the antecubital/forearm and dorsal hand veins for infusion and blood drawing, respectively. A primed (250 mU/m<sup>2</sup>/min) constant infusion (40 mU/m<sup>2</sup>/min) of insulin was delivered via peristaltic infusion pumps for 120&#x000a0;min. Plasma glucose samples were assessed every 5&#x000a0;min to maintain plasma glucose at 90&#x000a0;mg/d by adjusting the glucose infusion rate (GIR). Plasma insulin and free fatty acids (FFA) levels were also obtained at 0, 90, 105, and 120&#x000a0;min of the clamp, and values during the last 30&#x000a0;min were averaged to assess steady state levels. GIR was divided by steady&#x02010;state insulin to depict skeletal muscle (or peripheral) insulin sensitivity. Hepatic and adipose insulin resistance were estimated as we have done before by the product of fasting glucose and FFA by fasting insulin, respectively [<xref rid="osp470064-bib-0002" ref-type="bibr">2</xref>, <xref rid="osp470064-bib-0024" ref-type="bibr">24</xref>, <xref rid="osp470064-bib-0025" ref-type="bibr">25</xref>].</p></sec><sec id="osp470064-sec-0080"><label>2.6</label><title>Pancreatic Insulin Secretion</title><p>On a separate day from the clamp, participants reported to our CRC after an overnight fast of about 10&#x000a0;h. An intravenous line was placed in the antecubital vein for blood collection in people in a semi&#x02010;supine position. Blood was obtained for the determination of plasma glucose, insulin, C&#x02010;peptide, GLP&#x02010;1(active) and GIP at 0, 30, 60, 90, and 120&#x000a0;min. Glucose&#x02010;stimulated insulin secretion (GSIS) was calculated using total area under the curve (tAUC) during the OGTT by way of the trapezoidal rule [<xref rid="osp470064-bib-0002" ref-type="bibr">2</xref>, <xref rid="osp470064-bib-0026" ref-type="bibr">26</xref>]. C&#x02010;peptides were reconstructed by regularized deconvolution to&#x000a0;depict insulin secretion rates (ISR) [<xref rid="osp470064-bib-0027" ref-type="bibr">27</xref>]. GSIS was defined by dividing ISR tAUC by glucose tAUC. GSIS during early (0&#x02013;30&#x000a0;min) and total (0&#x02013;120&#x000a0;min) phases were adjusted for skeletal muscle insulin sensitivity from the clamp as well as the liver and adipose tissue to collectively characterize skeletal muscle, hepatic and adipose pancreatic function. Adjusting GSIS to individual indexes of insulin sensitivity was conducted to understand the complex interplay between key glucose regulatory organs as done before [<xref rid="osp470064-bib-0024" ref-type="bibr">24</xref>, <xref rid="osp470064-bib-0025" ref-type="bibr">25</xref>, <xref rid="osp470064-bib-0026" ref-type="bibr">26</xref>]. Hepatic insulin clearance was estimated by dividing tAUC of C&#x02010;peptide by insulin during the OGTT.</p></sec><sec id="osp470064-sec-0090"><label>2.7</label><title>Biochemical Analysis</title><p>Plasma glucose was analyzed by a glucose oxidase assay (YSI Instruments 2700, Yellow Springs, OH). The remaining samples were centrifuged at 4&#x000b0;C for 10&#x000a0;min at 3000 RPM and stored at &#x02212;80&#x000b0;C until later batched&#x02010;analyzed in duplicate to minimize variance within conditions. EDTA vacutainers with aprotinin were used to collect insulin, C&#x02010;peptide, and FFA. EDTA vacutainers with aprotinin and dipeptidyl peptidase&#x02010;4 (DPP&#x02010;IV) inhibitor were used for assessing GLP&#x02010;1(active, i.e. 7&#x02013;36 and 7&#x02010;37 amide) and GIP. These hormones were measured using an ELISA (Millipore, Billerica, MA), while FFAs were assessed by a colorimetric assay (Fuji, Richmond, VA).</p></sec><sec id="osp470064-sec-0100"><label>2.8</label><title>Statistical Analysis</title><p>R (The R Foundation, Vienna, Austria 2013) was used to analyze the data collected in the present work. Data were assessed for normality, and skewed data were log transformed for analysis. Independent, two&#x02010;tailed <italic toggle="yes">t</italic>&#x02010;tests were used to compare groups. Cohen's <italic toggle="yes">d</italic> effect size was calculated to assess physiological relevance between groups, and interpreted as small <italic toggle="yes">d</italic>&#x000a0;=&#x000a0;0.2, medium <italic toggle="yes">d</italic>&#x000a0;=&#x000a0;0.5, or large <italic toggle="yes">d</italic>&#x000a0;=&#x000a0;0.8, respectively. Associations were determined using Pearson's correlation. Significance was set at <italic toggle="yes">p</italic>&#x000a0;&#x02264;&#x000a0;0.05 and trends were accepted as 0.05&#x000a0;&#x0003c;&#x000a0;<italic toggle="yes">X</italic>&#x000a0;&#x02264;&#x000a0;0.10. Data were expressed as mean&#x000a0;&#x000b1;&#x000a0;SEM.</p></sec></sec><sec id="osp470064-sec-0110"><label>3</label><title>Results</title><sec id="osp470064-sec-0120"><label>3.1</label><title>Participant Characteristics</title><p>People with MORN and INT chronotypes did not significantly differ for age, body mass or composition, VO<sub>2</sub>max, blood pressure, or lipid levels (Table&#x000a0;<xref rid="osp470064-tbl-0001" ref-type="table">1</xref>). No group differences were noted for PSQI total composite score, sleep efficiency, or daytime drowsiness. However, INT had higher AST levels (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.05, <italic toggle="yes">d</italic>&#x000a0;=&#x000a0;0.67) and modest elevations in ALT (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.13, <italic toggle="yes">d</italic>&#x000a0;=&#x000a0;0.45) despite no difference in ALP levels.</p></sec><sec id="osp470064-sec-0130"><label>3.2</label><title>Clamp&#x02010;Derived Insulin Sensitivity</title><p>Fasting or steady state plasma glucose or FFA values during the clamp between MORN and INT were similar. However, fasting insulin was elevated in INT versus MORN (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.01). Skeletal muscle insulin sensitivity was also higher in MORN than INT (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.05, Table&#x000a0;<xref rid="osp470064-tbl-0002" ref-type="table">2</xref>). Moreover, hepatic (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.01) and adipose insulin resistance (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.03) were similarly lower in MORN versus INT (Table&#x000a0;<xref rid="osp470064-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="osp470064-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Insulin sensitivity measures between morning and intermediate chronotypes.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">MORN</th><th align="center" valign="bottom" rowspan="1" colspan="1">INT</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cohen's <italic toggle="yes">d</italic> effect size</th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" rowspan="1">Glucose</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fasted (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">105.4&#x000a0;&#x000b1;&#x000a0;2.9</td><td align="center" valign="top" rowspan="1" colspan="1">105.6&#x000a0;&#x000b1;&#x000a0;3.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.96</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Steady state (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">88.8&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">88.1&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.60</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Insulin</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fasted (uU/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">12.1&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">23.0&#x000a0;&#x000b1;&#x000a0;3.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.95</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Steady state (uU/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">80.5&#x000a0;&#x000b1;&#x000a0;3.8</td><td align="center" valign="top" rowspan="1" colspan="1">87.6&#x000a0;&#x000b1;&#x000a0;4.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td><td align="center" valign="top" rowspan="1" colspan="1">0.38</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Free fatty acids</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fasted (mEq/L)</td><td align="center" valign="top" rowspan="1" colspan="1">0.67&#x000a0;&#x000b1;&#x000a0;0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.67&#x000a0;&#x000b1;&#x000a0;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.98</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Steady state (mEq/L)</td><td align="center" valign="top" rowspan="1" colspan="1">0.16&#x000a0;&#x000b1;&#x000a0;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.16&#x000a0;&#x000b1;&#x000a0;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.78</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Clamp&#x02010;derived insulin sensitivity</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">GIR (mg/kg/min)</td><td align="center" valign="top" rowspan="1" colspan="1">2.4&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">2.0&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.48</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">GIR/Insulin (mg/kg/min/uU/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">0.035&#x000a0;&#x000b1;&#x000a0;0.003</td><td align="center" valign="top" rowspan="1" colspan="1">0.024&#x000a0;&#x000b1;&#x000a0;0.003</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HOMA&#x02010;IR (a.u.)</td><td align="center" valign="top" rowspan="1" colspan="1">3.2&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="center" valign="top" rowspan="1" colspan="1">6.1&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Adipose&#x02010;IR (a.u.)</td><td align="center" valign="top" rowspan="1" colspan="1">8.4&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="center" valign="top" rowspan="1" colspan="1">13.4&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.83</td></tr></tbody></table><table-wrap-foot id="osp470064-ntgp-0002"><fn id="osp470064-note-0004"><p>
<italic toggle="yes">Note:</italic> Data are expressed as mean&#x000a0;&#x000b1;&#x000a0;SEM. Euglycemic clamp was used to measure skeletal muscle insulin sensitivity. Homeostatic model of insulin resistance (HOMA&#x02010;IR) was calculated as fasting glucose <italic toggle="yes">x</italic> fasting insulin then divided by 405 to depict hepatic insulin resistance. Adipose&#x02010;IR was calculated as fasting FFA <italic toggle="yes">x</italic> fasting insulin to determine adipose insulin resistance.</p></fn><fn id="osp470064-note-0005"><p>Abbreviations: INT&#x000a0;=&#x000a0;intermediate chronotype; MORN&#x000a0;=&#x000a0;morning chronotype.</p></fn></table-wrap-foot></table-wrap></sec><sec id="osp470064-sec-0140"><label>3.3</label><title>OGTT Derived Glucose, Insulin and C &#x02010;Peptides</title><p>Consistent with HbA1c (Table&#x000a0;<xref rid="osp470064-tbl-0001" ref-type="table">1</xref>), fasting glucose, 2&#x02010;h glucose or early and total phase glucose tolerance were comparable in MORN and INT (Table&#x000a0;<xref rid="osp470064-tbl-0003" ref-type="table">3</xref>). However, consistent with clamp measures, insulin tended to be elevated in the fasted (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.11, <italic toggle="yes">d</italic>&#x000a0;=&#x000a0;0.59) and early phase insulin states (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.11, <italic toggle="yes">d</italic>&#x000a0;=&#x000a0;0.67) in INT compared with MORN during the OGTT. Fasting C&#x02010;peptides (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.15, <italic toggle="yes">d</italic>&#x000a0;=&#x000a0;0.48) along with an early phase C&#x02010;peptides (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.04, <italic toggle="yes">d</italic>&#x000a0;=&#x000a0;0.74) in INT paralleled circulating insulin versus MORN.</p><table-wrap position="float" id="osp470064-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Glucose metabolism during an OGTT between morning and intermediate chronotypes.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">MORN</th><th align="center" valign="bottom" rowspan="1" colspan="1">INT</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cohen's <italic toggle="yes">d</italic> effect size</th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" rowspan="1">Plasma glucose</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fasted (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">106.8&#x000a0;&#x000b1;&#x000a0;3.2</td><td align="center" valign="top" rowspan="1" colspan="1">100.9&#x000a0;&#x000b1;&#x000a0;3.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.39</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2&#x02010;h (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">144.8&#x000a0;&#x000b1;&#x000a0;7.5</td><td align="center" valign="top" rowspan="1" colspan="1">125.5&#x000a0;&#x000b1;&#x000a0;7.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.07</td><td align="center" valign="top" rowspan="1" colspan="1">0.54</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Early phase tAUC<sub>0&#x02013;30min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">4039.9&#x000a0;&#x000b1;&#x000a0;137.9</td><td align="center" valign="top" rowspan="1" colspan="1">4082.5&#x000a0;&#x000b1;&#x000a0;170.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.84</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Total phase tAUC<sub>0&#x02013;120min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">18878.0&#x000a0;&#x000b1;&#x000a0;832.0</td><td align="center" valign="top" rowspan="1" colspan="1">1741.9&#x000a0;&#x000b1;&#x000a0;944.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.37</td><td align="center" valign="top" rowspan="1" colspan="1">0.28</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Plasma insulin</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fasted (uU/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">13.3&#x000a0;&#x000b1;&#x000a0;1.2</td><td align="center" valign="top" rowspan="1" colspan="1">19.3&#x000a0;&#x000b1;&#x000a0;3.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.11</td><td align="center" valign="top" rowspan="1" colspan="1">0.59</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2&#x02010;h (uU/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">88.1&#x000a0;&#x000b1;&#x000a0;9.3</td><td align="center" valign="top" rowspan="1" colspan="1">86.3&#x000a0;&#x000b1;&#x000a0;17.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.93</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Early phase tAUC<sub>0&#x02013;30min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">1409.5&#x000a0;&#x000b1;&#x000a0;189.3</td><td align="center" valign="top" rowspan="1" colspan="1">2554.4&#x000a0;&#x000b1;&#x000a0;606.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.08</td><td align="center" valign="top" rowspan="1" colspan="1">0.67</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Total phase tAUC<sub>0&#x02013;120min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">9776.1&#x000a0;&#x000b1;&#x000a0;815.0</td><td align="center" valign="top" rowspan="1" colspan="1">13880.2&#x000a0;&#x000b1;&#x000a0;2542.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.14</td><td align="center" valign="top" rowspan="1" colspan="1">0.58</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Plasma C&#x02010;peptide</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fasted (ng/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">2.4&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="center" valign="top" rowspan="1" colspan="1">2.8&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.48</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2&#x02010;h (ng/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">8.5&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="center" valign="top" rowspan="1" colspan="1">8.7&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.89</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Early phase tAUC<sub>0&#x02013;30min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">122.0&#x000a0;&#x000b1;&#x000a0;6.7</td><td align="center" valign="top" rowspan="1" colspan="1">164.0&#x000a0;&#x000b1;&#x000a0;18.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.74</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Total phase tAUC<sub>0&#x02013;120min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">843.2&#x000a0;&#x000b1;&#x000a0;41.3</td><td align="center" valign="top" rowspan="1" colspan="1">936.6&#x000a0;&#x000b1;&#x000a0;90.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.36</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Insulin Secretion Rate</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fasted (ng/mL/min)</td><td align="center" valign="top" rowspan="1" colspan="1">0.2&#x000a0;&#x000b1;&#x000a0;0.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.4&#x000a0;&#x000b1;&#x000a0;0.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.81</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2&#x02010;h (ng/mL/min)</td><td align="center" valign="top" rowspan="1" colspan="1">0.4&#x000a0;&#x000b1;&#x000a0;0.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.4&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.93</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Early phase tAUC<sub>0&#x02013;30min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">12.6&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">16.9&#x000a0;&#x000b1;&#x000a0;2.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.07</td><td align="center" valign="top" rowspan="1" colspan="1">0.66</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Total phase tAUC<sub>0&#x02013;120min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">66.3&#x000a0;&#x000b1;&#x000a0;3.3</td><td align="center" valign="top" rowspan="1" colspan="1">70.8&#x000a0;&#x000b1;&#x000a0;7.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.58</td><td align="center" valign="top" rowspan="1" colspan="1">0.20</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">GSIS</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Early phase tAUC<sub>0&#x02013;30min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.0031&#x000a0;&#x000b1;&#x000a0;0.0001</td><td align="center" valign="top" rowspan="1" colspan="1">0.0042&#x000a0;&#x000b1;&#x000a0;0.0005</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.62</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Total phase tAUC<sub>0&#x02013;120min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.0035&#x000a0;&#x000b1;&#x000a0;0.0001</td><td align="center" valign="top" rowspan="1" colspan="1">0.0041&#x000a0;&#x000b1;&#x000a0;0.0005</td><td align="center" valign="top" rowspan="1" colspan="1">0.31</td><td align="center" valign="top" rowspan="1" colspan="1">0.38</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Plasma GLP&#x02010;1</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fasted (pg/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">8.7&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="center" valign="top" rowspan="1" colspan="1">7.3&#x000a0;&#x000b1;&#x000a0;1.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.55</td><td align="center" valign="top" rowspan="1" colspan="1">0.19</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2&#x02010;h (pg/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">7.6&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="center" valign="top" rowspan="1" colspan="1">10.2&#x000a0;&#x000b1;&#x000a0;2.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.39</td><td align="center" valign="top" rowspan="1" colspan="1">0.30</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Early phase tAUC<sub>0&#x02013;30min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">234.9&#x000a0;&#x000b1;&#x000a0;26.2</td><td align="center" valign="top" rowspan="1" colspan="1">292.2&#x000a0;&#x000b1;&#x000a0;46.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.29</td><td align="center" valign="top" rowspan="1" colspan="1">0.40</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Total phase tAUC<sub>0&#x02013;120min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">946.8&#x000a0;&#x000b1;&#x000a0;142.7</td><td align="center" valign="top" rowspan="1" colspan="1">1271.7&#x000a0;&#x000b1;&#x000a0;249.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.27</td><td align="center" valign="top" rowspan="1" colspan="1">0.44</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Plasma GIP</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fasted (pg/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">77.8&#x000a0;&#x000b1;&#x000a0;10.6</td><td align="center" valign="top" rowspan="1" colspan="1">92.7&#x000a0;&#x000b1;&#x000a0;12.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.37</td><td align="center" valign="top" rowspan="1" colspan="1">0.28</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2&#x02010;h (pg/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">334.8&#x000a0;&#x000b1;&#x000a0;25.9</td><td align="center" valign="top" rowspan="1" colspan="1">304.5&#x000a0;&#x000b1;&#x000a0;34.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.48</td><td align="center" valign="top" rowspan="1" colspan="1">0.23</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Early phase tAUC<sub>0&#x02013;30min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">6928.4&#x000a0;&#x000b1;&#x000a0;410.6</td><td align="center" valign="top" rowspan="1" colspan="1">6814.0&#x000a0;&#x000b1;&#x000a0;618.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.87</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Total phase tAUC<sub>0&#x02013;120min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">36919.4&#x000a0;&#x000b1;&#x000a0;2953.4</td><td align="center" valign="top" rowspan="1" colspan="1">40719.6&#x000a0;&#x000b1;&#x000a0;2352.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.32</td><td align="center" valign="top" rowspan="1" colspan="1">0.32</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Hepatic insulin clearance</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Early phase tAUC<sub>0&#x02013;30min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">10.7&#x000a0;&#x000b1;&#x000a0;4.0</td><td align="center" valign="top" rowspan="1" colspan="1">9.8&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.56</td><td align="center" valign="top" rowspan="1" colspan="1">0.21</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Total phase tAUC<sub>0&#x02013;120min</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">14.8&#x000a0;&#x000b1;&#x000a0;2.0</td><td align="center" valign="top" rowspan="1" colspan="1">11.6&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.28</td><td align="center" valign="top" rowspan="1" colspan="1">0.40</td></tr></tbody></table><table-wrap-foot id="osp470064-ntgp-0003"><fn id="osp470064-note-0006"><p>
<italic toggle="yes">Note:</italic> Data are expressed as mean&#x000a0;&#x000b1;&#x000a0;SEM.</p></fn><fn id="osp470064-note-0007"><p>Abbreviations: GIP&#x000a0;=&#x000a0;glucose insulinotropic polypeptide; GLP&#x02010;1&#x000a0;=&#x000a0;glucagon&#x02010;like polypeptide; GSIS&#x000a0;=&#x000a0;glucose&#x02010;stimulated insulin secretion rate (tAUC of ISR divided by Glucose); INT&#x000a0;=&#x000a0;intermediate chronotype; ISR&#x000a0;=&#x000a0;insulin secretion rate derived from deconvolution of plasma C&#x02010;peptide; MORN&#x000a0;=&#x000a0;morning chronotype; tAUC&#x000a0;=&#x000a0;total area under the curve.</p></fn></table-wrap-foot></table-wrap></sec><sec id="osp470064-sec-0150"><label>3.4</label><title>Pancreatic &#x003b2;&#x02010;cell Function</title><p>In line with insulin and C&#x02010;peptides, fasting ISR was also elevated in INT versus MORN (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.03, <italic toggle="yes">d</italic>&#x000a0;=&#x000a0;0.81) as was early phase ISR (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.07, <italic toggle="yes">d</italic>&#x000a0;=&#x000a0;0.66; Table&#x000a0;<xref rid="osp470064-tbl-0003" ref-type="table">3</xref>). Early phase GSIS mirrored higher levels in INT compared with MORN (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.10, <italic toggle="yes">d</italic>&#x000a0;=&#x000a0;0.62; Table&#x000a0;<xref rid="osp470064-tbl-0003" ref-type="table">3</xref>), although there was no statistical difference in total phase GSIS. Early phase skeletal muscle and adipose disposition index were similar between MORN and INT, although there were medium effect sizes for both total phase disposition indexes (Figure&#x000a0;<xref rid="osp470064-fig-0001" ref-type="fig">1</xref>). In contrast, the hepatic disposition index was significantly lower in INT compared with MORN (Figure&#x000a0;<xref rid="osp470064-fig-0001" ref-type="fig">1</xref>). No difference in GLP&#x02010;1(active) or GIP was noted between MORN and INT, nor was hepatic insulin clearance.</p><fig position="float" fig-type="FIGURE" id="osp470064-fig-0001"><label>FIGURE 1</label><caption><p>Morning versus Intermediate Chronotype on &#x003b2;&#x02010;cell function adjusted for multi&#x02010;organ insulin resistance. Data are expressed as mean&#x000a0;&#x000b1;&#x000a0;SEM. DI&#x000a0;=&#x000a0;disposition index and was used to characterize pancreatic &#x003b2;&#x02010;cell function. Skeletal muscle DI was calculated as the clamp&#x02010;derived glucose infusion rate divided by steady&#x02010;state insulin and multiplied by glucose&#x02010;stimulated insulin secretion (GSIS) during the first 30&#x000a0;min and total 120&#x000a0;min of an oral glucose tolerance test. Hepatic DI was estimated as GSIS divided by HOMA&#x02010;IR. Adipose DI was determined as GSIS divided by Adipose&#x02010;IR. GSIS was calculated as tAUC of ISR/Glucose at the respective timepoints. All &#x003b2;&#x02010;cell function data were log&#x02010;transformed for statistical analysis, but are shown here in raw values.</p></caption><graphic xlink:href="OSP4-11-e70064-g001" position="anchor" id="jats-graphic-1"/></fig></sec><sec id="osp470064-sec-0160"><label>3.5</label><title>Correlational Analysis</title><p>Early phase hepatic disposition index, but not skeletal muscle or adipose disposition index (data not shown), was related to early (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.32, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.05) and total tAUC GLP&#x02010;1 (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.37, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.03). AST was associated with higher early (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.41, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.01) and total phase insulin tAUC (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.41, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.01) as well as skeletal muscle insulin sensitivity (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;&#x02212;0.36, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.03), hepatic insulin resistance (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.37, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.02) and total phase skeletal muscle disposition index (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;&#x02212;0.37, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.02). ALT related to total phase insulin tAUC (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.34, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.02) and skeletal muscle insulin sensitivity (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;&#x02212;0.39, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.01) as well as hepatic insulin resistance (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.31, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.05) and adipose insulin resistance (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.36, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.05). ALT also related to skeletal muscle total phase disposition index (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;&#x02212;0.38, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.01). Skeletal muscle insulin sensitivity (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;&#x02212;0.36, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.02) as well as total phase skeletal muscle disposition index (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;&#x02212;0.31, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.05) correlated with circulating TG. The TG to HDL ratio was linked to fasting (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.30, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.05) and early phase ISR (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.31, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.04), total phase GSIS (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.30, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.05) and early (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;&#x02212;0.34, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.03) and total phase (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;&#x02212;0.41, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.01) skeletal muscle disposition index.</p></sec></sec><sec id="osp470064-sec-0170"><label>4</label><title>Discussion</title><p>The present work suggests that people with MORN chronotypes have lower early phase C&#x02010;peptides and higher &#x003b2;&#x02010;cell function adjusted for hepatic insulin resistance, independent of age, body composition and fitness when compared with individuals with INT chronotypes. Moreover, people with the MORN chronotype had higher skeletal muscle insulin sensitivity and lower hepatic and adipose insulin resistance. Despite lower C&#x02010;peptides and higher &#x003b2;&#x02010;cell function in those with MORN versus INT chronotype, glucose&#x02010;stimulated plasma GLP&#x02010;1(active) or GIP were not statistically different. However, plasma GLP&#x02010;1 tAUC did relate to &#x003b2;&#x02010;cell function when adjusted for hepatic insulin resistance. This is physiologically relevant as GSIS adjusted for multi&#x02010;organ insulin sensitivity provides an integrative view of glucose disposal in the body [<xref rid="osp470064-bib-0002" ref-type="bibr">2</xref>, <xref rid="osp470064-bib-0026" ref-type="bibr">26</xref>]. Intriguingly, it has been reported using 24&#x02010;h hyperglycemic clamp approaches that glucose infusion rate, but not glucose disposal, changed over the day in people with type 2 diabetes [<xref rid="osp470064-bib-0028" ref-type="bibr">28</xref>], suggesting that the liver is a primary organ under circadian regulation. Thus, the higher pancreatic &#x003b2;&#x02010;cell function observed in those with MORN chronotype is clinically important since prior work shows that declines in insulin secretion capacity are a stronger determinant of type 2 diabetes than insulin sensitivity [<xref rid="osp470064-bib-0029" ref-type="bibr">29</xref>].</p><p>There were no reported differences in subjective assessments of sleep or doziness in this study, suggesting that sleep does not likely explain differences in insulin secretion among chronotypes. This is consistent with prior work reporting higher type 2 diabetes risk in people with later chronotypes independent of sleep [<xref rid="osp470064-bib-0030" ref-type="bibr">30</xref>]. Prior studies, however, examining protocols mimicking large shifts in behavioral and environmental circadian cycles (e.g. shift work) demonstrated that early phase post&#x02010;prandial insulin is lower in the circadian evening by nearly 27% compared with morning [<xref rid="osp470064-bib-0031" ref-type="bibr">31</xref>, <xref rid="osp470064-bib-0032" ref-type="bibr">32</xref>]. Moreover, sleep restriction with circadian misalignment reduces insulin secretion capacity in healthy individuals, whereas circadian misalignment reduced insulin sensitivity only [<xref rid="osp470064-bib-0033" ref-type="bibr">33</xref>]. Melatonin is known to mediate sleep&#x02010;wake cycles, and it has been observed that lower nocturnal melatonin is related to insulin resistance [<xref rid="osp470064-bib-0034" ref-type="bibr">34</xref>] as well as people with later chronotypes [<xref rid="osp470064-bib-0034" ref-type="bibr">34</xref>]. This may be relevant to the current work since higher melatonin levels are reported in individuals with later versus early chronotypes during morning hours up to 12:00 [<xref rid="osp470064-bib-0035" ref-type="bibr">35</xref>]. Moreover, melatonin is suggested to decrease insulin secretion in cultured human islets [<xref rid="osp470064-bib-0036" ref-type="bibr">36</xref>], which is partly dependent on the gene variant melatonin receptor gene MTNR1B [<xref rid="osp470064-bib-0036" ref-type="bibr">36</xref>]. Interestingly, people with obesity and/or type 2 diabetes have been described to have inverted circadian systems, such that they are more insulin resistant and have lower insulin secretion in the morning than the evening (which is opposite of healthy controls) [<xref rid="osp470064-bib-0013" ref-type="bibr">13</xref>, <xref rid="osp470064-bib-0014" ref-type="bibr">14</xref>, <xref rid="osp470064-bib-0028" ref-type="bibr">28</xref>]. Taken together, additional work in people across chronotypes is needed to understand the physiology of circadian hormones related to glucose metabolism.</p><p>The current findings suggest that MORN chronotypes had higher pancreatic abilities to release the available pool of insulin granules (i.e. early phase) when compared with INT chronotypes, as evident by medium to large effect sizes. However, there appeared to be no difference between groups in the ability to synthesize insulin in response to ambient glucose during the OGTT (i.e. total phase). Considering the time&#x02010;course of insulin secretion may help explain why we observed differences in &#x003b2;&#x02010;cell function adjusted for hepatic insulin resistance compared with no overall difference in pancreatic function corrected for skeletal muscle or adipose insulin action. Indeed, adipose tissue requires subtle elevations above that of fasting insulin levels to suppress lipolysis [<xref rid="osp470064-bib-0037" ref-type="bibr">37</xref>], while normal late phase insulin secretion as depicted by our total phase indices should compensate for prevailing declines in skeletal muscle insulin sensitivity [<xref rid="osp470064-bib-0038" ref-type="bibr">38</xref>]. However, the reduced early phase insulin secretion in those with INT chronotype is of interest since the liver receives glucose initially upon absorption and requires &#x0223c;30&#x02013;60&#x000a0;min after rises in insulin and glucose to be fully suppressed [<xref rid="osp470064-bib-0038" ref-type="bibr">38</xref>]. A possible factor limiting the early phase insulin secretion response could relate to the incretins GLP&#x02010;1 and GIP, which stimulate nearly 60% of post&#x02010;prandial insulin secretion [<xref rid="osp470064-bib-0039" ref-type="bibr">39</xref>]. In fact, GLP&#x02010;1 correlated with hepatic disposition index, suggesting that higher GLP&#x02010;1 levels may have contributed to people with MORN chronotype showcasing higher GSIS adjusted to hepatic insulin resistance. How chronobiology impacted incretins is beyond the scope of this work, but incretins do act on insulin secretion via amplifying pathways (e.g. cAMP, glutamate, etc.) compared with ingested glucose acting on triggering pathways (i.e. Ca<sup>++</sup> mediated) [<xref rid="osp470064-bib-0040" ref-type="bibr">40</xref>]. Therefore, additional work examining the mechanism(s) by which chronobiology regulates pancreatic &#x003b2;&#x02010;cell function is warranted.</p><p>Another consideration is that the enzymes AST and ALT have conventionally been used to reflect hepatic injury and/or fatty infiltration [<xref rid="osp470064-bib-0041" ref-type="bibr">41</xref>], which has been linked to elevated FFA from visceral adipose tissue draining into the liver and inducing insulin resistance [<xref rid="osp470064-bib-0042" ref-type="bibr">42</xref>]. Interestingly, individuals with INT chronotype herein presented with higher AST levels and modest effects for ALT (albeit not&#x02010;statistically significant) when compared with people with MORN chronotypes. Although those with INT had similar visceral fat levels as determined from DXA when compared with people with the MORN chronotype, people with INT chronotype had higher adipose insulin resistance than those with the MORN chronotype. In fact, the similar FFA levels between chronotypes suggest that the excess insulin was needed, and sufficient to suppress lipolysis and/or clear FFA for re&#x02010;esterification among those with INT chronotype. However, it should be acknowledged that AST is not only found in liver tissue but also in other tissues such as skeletal muscle, gut, heart, bone, brain and &#x003b2;&#x02010;cells [<xref rid="osp470064-bib-0043" ref-type="bibr">43</xref>]. Indeed, AST is considered an important enzyme in pancreatic &#x003b2;&#x02010;cells that plays roles in transferring amino acids to the formation of citrate levels, which contributes to insulin secretion [<xref rid="osp470064-bib-0039" ref-type="bibr">39</xref>]. Prior work demonstrates that people with later chronotypes had elevations in glutamine as well as the TCA intermediates: isocitrate, alpha&#x02010;ketoglutarate, succinate, fumarate, malate and oxaloacetate [<xref rid="osp470064-bib-0002" ref-type="bibr">2</xref>]. These later observations of metabolites along with higher AST in INT herein support the idea that people with INT chronotype have alterations in &#x003b2;&#x02010;cell metabolism [<xref rid="osp470064-bib-0015" ref-type="bibr">15</xref>]. Indeed, elevations in AST and ALT have been associated with type 2 diabetes risk as well as declines in insulin secretion as estimated from fasting glucose and insulin (i.e. HOMA&#x02010;B) [<xref rid="osp470064-bib-0044" ref-type="bibr">44</xref>].</p><p>There are limitations to this study. The groups comprised mostly women of different menstrual status. However, the percentage of pre&#x02010;, peri&#x02010; and post&#x02010;menopausal status was similar, suggesting that menstrual status is unlikely to be a main factor contributing to group differences. This study also did not have a lean control reference group to identify the role of body fat. Therefore, these findings may not be extrapolated to adults with varying weight status. Moreover, this study did not include people with evening chronotype, and people did present with impaired fasting glucose. It is generally viewed that individuals with evening chronotypes have a higher risk for type 2 diabetes than people with INT or MORN chronotypes, and the modest elevations in blood glucose suggest impairments in &#x003b2;&#x02010;cell function are not unanticipated. However, it remains important to note that despite no overall differences in glucose tolerance or HbA1c, people with INT chronotype demonstrated declines in both insulin sensitivity and pancreatic function more so than those with MORN. Testing was conducted in the morning hours, and it is possible that physiologic responses to a glucose load between chronotypes may differ if testing was conducted in the afternoon. An OGTT was used in this study to assess pancreatic function, and these results may not be generalizable to a mixed&#x02010;meal despite generally comparable responses as discussed before [<xref rid="osp470064-bib-0045" ref-type="bibr">45</xref>]. Furthermore, using intravenous glucose methods would enable the assessment of insulin secretion independent of gut hormones. However, the OGTT provides ecological value and is physiologically relevant for assessment of incretins. Lastly, HOMA&#x02010;IR and Adipose&#x02010;IR approaches [<xref rid="osp470064-bib-0002" ref-type="bibr">2</xref>, <xref rid="osp470064-bib-0026" ref-type="bibr">26</xref>] may under&#x02010; or over&#x02010;estimate differences in organ&#x02010;specific insulin action compared with stable isotopes despite being valid assessments.</p><p>In conclusion, people with MORN chronotypes have lower fasting insulin secretion rates and higher pancreatic &#x003b2;&#x02010;cell function when adjusted for hepatic but not skeletal muscle or adipose insulin sensitivity independent of age, body composition, fitness, or sleep. Interestingly, GLP&#x02010;1 related to higher pancreatic &#x003b2;&#x02010;cell function and lower AST correlated with lower GSIS. Together, these data suggest that people with MORN chronotype present with higher pancreatic function to regulate glycemia among people with obesity. Additional work is needed to clarify the role of chronotype on the crosstalk between pancreatic &#x003b2;&#x02010;cells and insulin sensitive tissues in order to optimize treatments that lower type 2 diabetes risk in people with obesity.</p></sec><sec id="osp470064-sec-0180"><title>Author Contributions</title><p>Conceptualization (S.K.M.); methodology (S.K.M.); formal analysis, (M.M.E.R., C.F., and S.K.M.); investigation (M.M.E.R., E.M.H., A.M.S. and S.K.M.); writing&#x02013;original draft preparation (M.M.E.R. and S.K.M.); writing&#x02013;review and editing (E.M.H., C.F., and A.M.S.); supervision (S.K.M.); project administration (S.K.M.); funding acquisition (S.K.M.). All authors have read and agreed to the published version of the manuscript.</p></sec><sec sec-type="COI-statement" id="osp470064-sec-0200"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="osp470064-sec-0190"><title>Acknowledgments</title><p>We thank the Applied Metabolism &#x00026; Physiology Lab members involved in this work, and all research volunteers for their study involvement. We also thank the Clinical Research Center staff for technical assistance, Dr. Eugene J. Barrett<sup>,</sup> M.D. for medical guidance, and Ms. Lisa Farr, M.Ed. for fitness testing assistance. Funding for this work was supported by National Institutes of Health RO1&#x02010;HL130296 (S.K.M.).</p></ack><sec sec-type="data-availability" id="osp470064-sec-0220"><title>Data Availability Statement</title><p>These data have not been made publicly available. However, the corresponding author (SKM) can provide further information on the data upon reasonable request.</p></sec><ref-list content-type="cited-references" id="osp470064-bibl-0001"><title>References</title><ref id="osp470064-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="osp470064-cit-0001">
<string-name>
<given-names>T.</given-names>
<surname>Anothaisintawee</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Lertrattananon</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Thamakaison</surname>
</string-name>, <string-name>
<given-names>K. L.</given-names>
<surname>Knutson</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Thakkinstian</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Reutrakul</surname>
</string-name>, &#x0201c;<article-title>Later Chronotype Is Associated With Higher Hemoglobin A1c in Prediabetes Patients</article-title>,&#x0201d; <source>Chronobiology International</source>
<volume>34</volume>, no. <issue>3</issue> (<year>2017</year>): <fpage>393</fpage>&#x02013;<lpage>402</lpage>, <pub-id pub-id-type="doi">10.1080/07420528.2017.1279624</pub-id>.<pub-id pub-id-type="pmid">28128995</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="osp470064-cit-0002">
<string-name>
<given-names>M. M. E.</given-names>
<surname>Remchak</surname>
</string-name>, <string-name>
<given-names>E. M.</given-names>
<surname>Heiston</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Ballantyne</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Insulin Sensitivity and Metabolic Flexibility Parallel Plasma TCA Levels in Early Chronotype With Metabolic Syndrome</article-title>,&#x0201d; <source>Journal of Clinical Endocrinology &#x00026; Metabolism</source>
<volume>107</volume>, no. <issue>8</issue> (April 16, <year>2022</year>): <elocation-id>dgac233</elocation-id>, <pub-id pub-id-type="doi">10.1210/clinem/dgac233</pub-id>.</mixed-citation></ref><ref id="osp470064-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="osp470064-cit-0003">
<string-name>
<given-names>I. C.</given-names>
<surname>Mason</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Qian</surname>
</string-name>, <string-name>
<given-names>G. K.</given-names>
<surname>Adler</surname>
</string-name>, and <string-name>
<given-names>F. A. J. L.</given-names>
<surname>Scheer</surname>
</string-name>, &#x0201c;<article-title>Impact of Circadian Disruption on Glucose Metabolism: Implications for Type 2 Diabetes</article-title>,&#x0201d; <source>Diabetologia</source>
<volume>63</volume>, no. <issue>3</issue> (<year>2020</year>): <fpage>462</fpage>&#x02013;<lpage>472</lpage>, <pub-id pub-id-type="doi">10.1007/s00125-019-05059-6</pub-id>.<pub-id pub-id-type="pmid">31915891</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="osp470064-cit-0004">
<string-name>
<given-names>R. A.</given-names>
<surname>DeFronzo</surname>
</string-name> and <string-name>
<given-names>M. A.</given-names>
<surname>Abdul&#x02010;Ghani</surname>
</string-name>, &#x0201c;<article-title>Preservation of &#x003b2;&#x02010;Cell Function: The Key to Diabetes Prevention</article-title>,&#x0201d; <source>Journal of Clinical Endocrinology &#x00026; Metabolism</source>
<volume>96</volume>, no. <issue>8</issue> (<year>2011</year>): <fpage>2354</fpage>&#x02013;<lpage>2366</lpage>, <pub-id pub-id-type="doi">10.1210/jc.2011-0246</pub-id>.<pub-id pub-id-type="pmid">21697254</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="osp470064-cit-0005">
<string-name>
<given-names>H. J.</given-names>
<surname>Roberts</surname>
</string-name>, &#x0201c;<article-title>Afternoon Glucose Tolerance Testing: A Key to the Pathogenesis, Early Diagnosis and Prognosis of Diabetogenic Hyperinsulinism</article-title>,&#x0201d; <source>Journal of the American Geriatrics Society</source>
<volume>12</volume>, no. <issue>5</issue> (<year>1964</year>): <fpage>423</fpage>&#x02013;<lpage>472</lpage>, <pub-id pub-id-type="doi">10.1111/j.1532-5415.1964.tb05730.x</pub-id>.<pub-id pub-id-type="pmid">14157686</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="osp470064-cit-0006">
<string-name>
<given-names>E.</given-names>
<surname>Van Cauter</surname>
</string-name>, <string-name>
<given-names>K. S.</given-names>
<surname>Polonsky</surname>
</string-name>, and <string-name>
<given-names>A. J.</given-names>
<surname>Scheen</surname>
</string-name>, &#x0201c;<article-title>Roles of Circadian Rhythmicity and Sleep in Human Glucose Regulation</article-title>,&#x0201d; <source>Endocrine Reviews</source>
<volume>18</volume>, no. <issue>5</issue> (<year>1997</year>): <fpage>716</fpage>&#x02013;<lpage>738</lpage>, <pub-id pub-id-type="doi">10.1210/edrv.18.5.0317</pub-id>.<pub-id pub-id-type="pmid">9331550</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="osp470064-cit-0007">
<string-name>
<given-names>T.</given-names>
<surname>Gibson</surname>
</string-name> and <string-name>
<given-names>R. J.</given-names>
<surname>Jarrett</surname>
</string-name>, &#x0201c;<article-title>Diurnal Variation in Insulin Sensitivity</article-title>,&#x0201d; <source>Lancet</source>
<volume>300</volume>, no. <issue>7784</issue> (<year>1972</year>): <fpage>947</fpage>&#x02013;<lpage>948</lpage>, <pub-id pub-id-type="doi">10.1016/S0140-6736(72)92472-5</pub-id>.</mixed-citation></ref><ref id="osp470064-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="osp470064-cit-0008">
<string-name>
<given-names>G.</given-names>
<surname>Boden</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Ruiz</surname>
</string-name>, <string-name>
<given-names>J. L.</given-names>
<surname>Urbain</surname>
</string-name>, and <string-name>
<given-names>X.</given-names>
<surname>Chen</surname>
</string-name>, &#x0201c;<article-title>Evidence for a Circadian Rhythm of Insulin Secretion</article-title>,&#x0201d; <source>American Journal of Physiology. Endocrinology and Metabolism</source>
<volume>271</volume>, no. <issue>2</issue> (<year>1996</year>): <fpage>E246</fpage>&#x02013;<lpage>E252</lpage>, <pub-id pub-id-type="doi">10.1152/ajpendo.1996.271.2.E246</pub-id>.</mixed-citation></ref><ref id="osp470064-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="osp470064-cit-0009">
<string-name>
<given-names>A.</given-names>
<surname>Saad</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Dalla Man</surname>
</string-name>, <string-name>
<given-names>D. K.</given-names>
<surname>Nandy</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Diurnal Pattern to Insulin Secretion and Insulin Action in Healthy Individuals</article-title>,&#x0201d; <source>Diabetes</source>
<volume>61</volume>, no. <issue>11</issue> (<year>2012</year>): <fpage>2691</fpage>&#x02013;<lpage>2700</lpage>, <pub-id pub-id-type="doi">10.2337/db11-1478</pub-id>.<pub-id pub-id-type="pmid">22751690</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="osp470064-cit-0010">
<string-name>
<given-names>E.</given-names>
<surname>Peschke</surname>
</string-name> and <string-name>
<given-names>D.</given-names>
<surname>Peschke</surname>
</string-name>, &#x0201c;<article-title>Evidence for a Circadian Rhythm of Insulin Release From Perifused Rat Pancreatic Islets</article-title>,&#x0201d; <source>Diabetologia</source>
<volume>41</volume>, no. <issue>9</issue> (<year>1998</year>): <fpage>1085</fpage>&#x02013;<lpage>1092</lpage>, <pub-id pub-id-type="doi">10.1007/s001250051034</pub-id>.<pub-id pub-id-type="pmid">9754828</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="osp470064-cit-0011">
<string-name>
<given-names>C.</given-names>
<surname>Saini</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Petrenko</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Pulimeno</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A Functional Circadian Clock Is Required for Proper Insulin Secretion by Human Pancreatic Islet Cells</article-title>,&#x0201d; <source>Diabetes, Obesity and Metabolism</source>
<volume>18</volume>, no. <issue>4</issue> (<year>2016</year>): <fpage>355</fpage>&#x02013;<lpage>365</lpage>, <pub-id pub-id-type="doi">10.1111/dom.12616</pub-id>.</mixed-citation></ref><ref id="osp470064-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="osp470064-cit-0012">
<string-name>
<given-names>M.</given-names>
<surname>Perelis</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Marcheva</surname>
</string-name>, <string-name>
<given-names>K. M.</given-names>
<surname>Ramsey</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Pancreatic &#x003b2;&#x02010;cell Enhancers Regulate Rhythmic Transcription of Genes Controlling Insulin Secretion</article-title>,&#x0201d; <source>Science</source>
<volume>350</volume>, no. <issue>6261</issue> (<year>2015</year>): <elocation-id>aac4250</elocation-id>, <pub-id pub-id-type="doi">10.1126/science.aac4250</pub-id>.<pub-id pub-id-type="pmid">26542580</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="osp470064-cit-0013">
<string-name>
<given-names>A.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Ader</surname>
</string-name>, <string-name>
<given-names>G. A.</given-names>
<surname>Bray</surname>
</string-name>, and <string-name>
<given-names>R. N.</given-names>
<surname>Bergman</surname>
</string-name>, &#x0201c;<article-title>Diurnal Variation in Glucose Tolerance: Cyclic Suppression of Insulin Action and Insulin Secretion in Normal&#x02010;Weight, but Not Obese, Subjects</article-title>,&#x0201d; <source>Diabetes</source>
<volume>41</volume>, no. <issue>6</issue> (<year>1992</year>): <fpage>750</fpage>&#x02013;<lpage>759</lpage>, <pub-id pub-id-type="doi">10.2337/diab.41.6.750</pub-id>.<pub-id pub-id-type="pmid">1587401</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="osp470064-cit-0014">
<string-name>
<given-names>P. Z.</given-names>
<surname>Zimmet</surname>
</string-name>, <string-name>
<given-names>J. R.</given-names>
<surname>Wall</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Rome</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Stimmler</surname>
</string-name>, and <string-name>
<given-names>R. J.</given-names>
<surname>Jarrett</surname>
</string-name>, &#x0201c;<article-title>Diurnal Variation in Glucose Tolerance: Associated Changes in Plasma Insulin, Growth Hormone, and Non&#x02010;esterified</article-title>,&#x0201d; <source>British Medical Journal</source>
<volume>1</volume>, no. <issue>5906</issue> (<year>1974</year>): <fpage>485</fpage>&#x02013;<lpage>488</lpage>, <pub-id pub-id-type="doi">10.1136/bmj.1.5906.485</pub-id>.<pub-id pub-id-type="pmid">4817159</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="osp470064-cit-0015">
<string-name>
<given-names>P.</given-names>
<surname>Newsholme</surname>
</string-name> and <string-name>
<given-names>M.</given-names>
<surname>Krause</surname>
</string-name>, &#x0201c;<article-title>Nutritional Regulation of Insulin Secretion: Implications for Diabetes</article-title>,&#x0201d; <source>Clinical Biochemist Reviews</source>
<volume>33</volume>, no. <issue>2</issue> (<year>2012</year>): <fpage>35</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">22896743</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="osp470064-cit-0016">
<string-name>
<given-names>M. M. E.</given-names>
<surname>Remchak</surname>
</string-name>, <string-name>
<given-names>E. M.</given-names>
<surname>Heiston</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Ballantyne</surname>
</string-name>, <string-name>
<given-names>B. L.</given-names>
<surname>Dotson</surname>
</string-name>, and <string-name>
<given-names>S. K.</given-names>
<surname>Malin</surname>
</string-name>, &#x0201c;<article-title>Aortic Waveform Responses to Insulin in Late Versus Early Chronotype With Metabolic Syndrome</article-title>,&#x0201d; <source>Physics Reports</source>
<volume>10</volume>, no. <issue>20</issue> (<year>2022</year>): <elocation-id>e15473</elocation-id>, <pub-id pub-id-type="doi">10.14814/phy2.15473</pub-id>.</mixed-citation></ref><ref id="osp470064-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="osp470064-cit-0017">
<string-name>
<given-names>M.</given-names>
<surname>Kanat</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Mari</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Norton</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Distinct &#x003b2;&#x02010;Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance</article-title>,&#x0201d; <source>Diabetes</source>
<volume>61</volume>, no. <issue>2</issue> (<year>2012</year>): <fpage>447</fpage>&#x02013;<lpage>453</lpage>, <pub-id pub-id-type="doi">10.2337/db11-0995</pub-id>.<pub-id pub-id-type="pmid">22275086</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="osp470064-cit-0018">
<string-name>
<given-names>D.</given-names>
<surname>Fischer</surname>
</string-name>, <string-name>
<given-names>D. A.</given-names>
<surname>Lombardi</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Marucci&#x02010;Wellman</surname>
</string-name>, and <string-name>
<given-names>T.</given-names>
<surname>Roenneberg</surname>
</string-name>, &#x0201c;<article-title>Chronotypes in the US &#x02013; Influence of Age and Sex</article-title>,&#x0201d; <source>PLoS One</source>
<volume>12</volume>, no. <issue>6</issue> (<year>2017</year>): <elocation-id>e0178782</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0178782</pub-id>.<pub-id pub-id-type="pmid">28636610</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="osp470064-cit-0019">
<string-name>
<given-names>S.</given-names>
<surname>Crook</surname>
</string-name>, <string-name>
<given-names>N. A.</given-names>
<surname>Sievi</surname>
</string-name>, <string-name>
<given-names>K. E.</given-names>
<surname>Bloch</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Minimum Important Difference of the Epworth Sleepiness Scale in Obstructive Sleep Apnoea: Estimation From Three Randomised Controlled Trials</article-title>,&#x0201d; <source>Thorax</source>
<volume>74</volume>, no. <issue>4</issue> (<year>2019</year>): <fpage>390</fpage>&#x02013;<lpage>396</lpage>, <pub-id pub-id-type="doi">10.1136/thoraxjnl-2018-211959</pub-id>.<pub-id pub-id-type="pmid">30100576</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="osp470064-cit-0020">
<string-name>
<given-names>J. C.</given-names>
<surname>Cole</surname>
</string-name>, <string-name>
<given-names>S. J.</given-names>
<surname>Motivala</surname>
</string-name>, <string-name>
<given-names>D. J.</given-names>
<surname>Buysse</surname>
</string-name>, <string-name>
<given-names>M. N.</given-names>
<surname>Oxman</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Levin</surname>
</string-name>, and <string-name>
<given-names>M. R.</given-names>
<surname>Irwin</surname>
</string-name>, &#x0201c;<article-title>Validation of a 3&#x02010;Factor Scoring Model for the Pittsburgh Sleep Quality Index in Older Adults</article-title>,&#x0201d; <source>Sleep</source>
<volume>29</volume>, no. <issue>1</issue> (<year>2006</year>): <fpage>112</fpage>&#x02013;<lpage>116</lpage>, <pub-id pub-id-type="doi">10.1093/sleep/29.1.112</pub-id>.<pub-id pub-id-type="pmid">16453989</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="osp470064-cit-0021">
<string-name>
<given-names>P. T.</given-names>
<surname>Katzmarzyk</surname>
</string-name>, <string-name>
<given-names>K. E.</given-names>
<surname>Powell</surname>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Jakicic</surname>
</string-name>, <string-name>
<given-names>R. P.</given-names>
<surname>Troiano</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Piercy</surname>
</string-name>, and <string-name>
<given-names>B.</given-names>
<surname>Tennant</surname>
</string-name>, &#x0201c;<article-title>Sedentary Behavior and Health: Update From the 2018 Physical Activity Guidelines Advisory Committee</article-title>,&#x0201d; <source>Medicine &#x00026; Science in Sports &#x00026; Exercise</source>
<volume>51</volume>, no. <issue>6</issue> (<year>2019</year>): <fpage>15</fpage>&#x02013;<lpage>1241</lpage>, <pub-id pub-id-type="doi">10.1249/MSS.0000000000001935</pub-id>.</mixed-citation></ref><ref id="osp470064-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="osp470064-cit-0022">
<string-name>
<given-names>B. L.</given-names>
<surname>Dotson</surname>
</string-name>, <string-name>
<given-names>E. M.</given-names>
<surname>Heiston</surname>
</string-name>, <string-name>
<given-names>S. L.</given-names>
<surname>Miller</surname>
</string-name>, and <string-name>
<given-names>S. K.</given-names>
<surname>Malin</surname>
</string-name>, &#x0201c;<article-title>Insulin Stimulation Reduces Aortic Wave Reflection in Adults With Metabolic Syndrome</article-title>,&#x0201d; <source>American Journal of Physiology &#x02010; Heart and Circulatory Physiology</source>
<volume>320</volume>, no. <issue>6</issue> (<year>2021</year>): <fpage>H2305</fpage>&#x02013;<lpage>H2312</lpage>, <pub-id pub-id-type="doi">10.1152/ajpheart.00975.2020</pub-id>.<pub-id pub-id-type="pmid">33861146</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="osp470064-cit-0023">
<string-name>
<given-names>E. M.</given-names>
<surname>Heiston</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Ballantyne</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Kranz</surname>
</string-name>, and <string-name>
<given-names>S. K.</given-names>
<surname>Malin</surname>
</string-name>, &#x0201c;<article-title>A Single Bout of Exercise Improves Vascular Insulin Sensitivity in Adults With Obesity</article-title>,&#x0201d; <source>Obesity</source>
<volume>29</volume>, no. <issue>9</issue> (<year>2021</year>): <fpage>1487</fpage>&#x02013;<lpage>1496</lpage>, <pub-id pub-id-type="doi">10.1002/oby.23229</pub-id>.<pub-id pub-id-type="pmid">34339111</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="osp470064-cit-0024">
<string-name>
<given-names>S. K.</given-names>
<surname>Malin</surname>
</string-name>, <string-name>
<given-names>M. E.</given-names>
<surname>Francois</surname>
</string-name>, <string-name>
<given-names>N. Z. M.</given-names>
<surname>Eichner</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Impact of Short&#x02010;Term Exercise Training Intensity on &#x003b2;&#x02010;cell Function in Older Obese Adults With Prediabetes</article-title>,&#x0201d; <source>Journal of Applied Physiology</source>
<volume>125</volume>, no. <issue>6</issue> (<year>2018</year>): <fpage>1979</fpage>&#x02013;<lpage>1986</lpage>, <pub-id pub-id-type="doi">10.1152/japplphysiol.00680.2018</pub-id>.<pub-id pub-id-type="pmid">30307821</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="osp470064-cit-0025">
<string-name>
<given-names>S. K.</given-names>
<surname>Malin</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Frick</surname>
</string-name>, <string-name>
<given-names>W. S.</given-names>
<surname>Wisseman</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>&#x003b2;&#x02010;Cell Function During a High&#x02010;Fat Meal in Young Versus Old Adults: Role of Exercise</article-title>,&#x0201d; <source>American Journal of Physiology &#x02010; Regulatory, Integrative and Comparative Physiology</source>
<volume>325</volume>, no. <issue>2</issue> (<year>2023</year>): <fpage>R164</fpage>&#x02013;<lpage>R171</lpage>, <pub-id pub-id-type="doi">10.1152/ajpregu.00047.2023</pub-id>.<pub-id pub-id-type="pmid">37306399</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="osp470064-cit-0026">
<string-name>
<given-names>C.</given-names>
<surname>Br&#x000f8;ns</surname>
</string-name>, <string-name>
<given-names>C. B.</given-names>
<surname>Jensen</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Storgaard</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Impact of Short&#x02010;Term High&#x02010;Fat Feeding on Glucose and Insulin Metabolism in Young Healthy Men</article-title>,&#x0201d; <source>Journal of Physiology (Cambridge)</source>
<volume>587</volume>, no. <issue>Pt 10</issue> (<year>2009</year>): <fpage>2387</fpage>&#x02013;<lpage>2397</lpage>, <pub-id pub-id-type="doi">10.1113/jphysiol.2009.169078</pub-id>.</mixed-citation></ref><ref id="osp470064-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="osp470064-cit-0027">
<string-name>
<given-names>E. V.</given-names>
<surname>Cauter</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Mestrez</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Sturis</surname>
</string-name>, and <string-name>
<given-names>K. S.</given-names>
<surname>Polonsky</surname>
</string-name>, &#x0201c;<article-title>Estimation of Insulin Secretion Rates From C&#x02010;Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C&#x02010;Peptide Clearance</article-title>,&#x0201d; <source>Diabetes</source>
<volume>41</volume>, no. <issue>3</issue> (<year>1992</year>): <fpage>368</fpage>&#x02013;<lpage>377</lpage>, <pub-id pub-id-type="doi">10.2337/diab.41.3.368</pub-id>.<pub-id pub-id-type="pmid">1551497</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="osp470064-cit-0028">
<string-name>
<given-names>G.</given-names>
<surname>Boden</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Chen</surname>
</string-name>, and <string-name>
<given-names>J. L.</given-names>
<surname>Urbain</surname>
</string-name>, &#x0201c;<article-title>Evidence for a Circadian Rhythm of Insulin Sensitivity in Patients With NIDDM Caused by Cyclic Changes in Hepatic Glucose Production</article-title>,&#x0201d; <source>Diabetes</source>
<volume>45</volume>, no. <issue>8</issue> (<year>1996</year>): <fpage>1044</fpage>&#x02013;<lpage>1050</lpage>, <pub-id pub-id-type="doi">10.2337/diab.45.8.1044</pub-id>.<pub-id pub-id-type="pmid">8690150</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="osp470064-cit-0029">
<string-name>
<given-names>K. M.</given-names>
<surname>Utzschneider</surname>
</string-name>, <string-name>
<given-names>R. L.</given-names>
<surname>Prigeon</surname>
</string-name>, <string-name>
<given-names>M. V.</given-names>
<surname>Faulenbach</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Oral Disposition Index Predicts the Development of Future Diabetes Above and Beyond Fasting and 2&#x02010;h Glucose Levels</article-title>,&#x0201d; <source>Diabetes Care</source>
<volume>32</volume>, no. <issue>2</issue> (<year>2009</year>): <fpage>335</fpage>&#x02013;<lpage>341</lpage>, <pub-id pub-id-type="doi">10.2337/dc08-1478</pub-id>.<pub-id pub-id-type="pmid">18957530</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="osp470064-cit-0030">
<string-name>
<given-names>S.</given-names>
<surname>Reutrakul</surname>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>Hood</surname>
</string-name>, <string-name>
<given-names>S. J.</given-names>
<surname>Crowley</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Chronotype Is Independently Associated With Glycemic Control in Type 2 Diabetes</article-title>,&#x0201d; <source>Diabetes Care</source>
<volume>36</volume>, no. <issue>9</issue> (<year>2013</year>): <fpage>2523</fpage>&#x02013;<lpage>2529</lpage>, <pub-id pub-id-type="doi">10.2337/dc12-2697</pub-id>.<pub-id pub-id-type="pmid">23637357</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="osp470064-cit-0031">
<string-name>
<given-names>C. J.</given-names>
<surname>Morris</surname>
</string-name>, <string-name>
<given-names>J. N.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>J. I.</given-names>
<surname>Garcia</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Endogenous Circadian System and Circadian Misalignment Impact Glucose Tolerance via Separate Mechanisms in Humans</article-title>,&#x0201d; <source>Proceedings of the National Academy of Sciences</source>
<volume>112</volume>, no. <issue>17</issue> (<year>2015</year>): <fpage>E2225</fpage>&#x02013;<lpage>E2234</lpage>, <pub-id pub-id-type="doi">10.1073/pnas.1418955112</pub-id>.</mixed-citation></ref><ref id="osp470064-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="osp470064-cit-0032">
<string-name>
<given-names>J.</given-names>
<surname>Qian</surname>
</string-name>, <string-name>
<given-names>C. D.</given-names>
<surname>Man</surname>
</string-name>, <string-name>
<given-names>C. J.</given-names>
<surname>Morris</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Cobelli</surname>
</string-name>, and <string-name>
<given-names>F. A.</given-names>
<surname>Scheer</surname>
</string-name>, &#x0201c;<article-title>Differential Effects of the Circadian System and Circadian Misalignment on Insulin Sensitivity and Insulin Secretion in Humans</article-title>,&#x0201d; <source>Diabetes, Obesity and Metabolism</source>
<volume>20</volume>, no. <issue>10</issue> (<year>2018</year>): <fpage>2481</fpage>&#x02013;<lpage>2485</lpage>, <pub-id pub-id-type="doi">10.1111/dom.13391</pub-id>.</mixed-citation></ref><ref id="osp470064-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="osp470064-cit-0033">
<string-name>
<given-names>O. M.</given-names>
<surname>Buxton</surname>
</string-name>, <string-name>
<given-names>S. W.</given-names>
<surname>Cain</surname>
</string-name>, <string-name>
<given-names>S. P.</given-names>
<surname>O&#x02019;Connor</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Metabolic Consequences in Humans of Prolonged Sleep Restriction Combined With Circadian Disruption</article-title>,&#x0201d; <source>Science Translational Medicine</source>
<volume>4</volume>, no. <issue>129</issue> (<year>2012</year>): <elocation-id>129ra43</elocation-id>, <pub-id pub-id-type="doi">10.1126/scitranslmed.3003200</pub-id>.</mixed-citation></ref><ref id="osp470064-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="osp470064-cit-0034">
<string-name>
<given-names>J.</given-names>
<surname>Overberg</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Kalveram</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Keller</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Krude</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>K&#x000fc;hnen</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Wiegand</surname>
</string-name>, &#x0201c;<article-title>Interactions Between Nocturnal Melatonin Secretion, Metabolism, and Sleeping Behavior in Adolescents With Obesity</article-title>,&#x0201d; <source>International Journal of Obesity</source>
<volume>46</volume>, no. <issue>5</issue> (<year>2022</year>): <fpage>1051</fpage>&#x02013;<lpage>1058</lpage>, <pub-id pub-id-type="doi">10.1038/s41366-022-01077-4</pub-id>.<pub-id pub-id-type="pmid">35140394</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="osp470064-cit-0035">
<string-name>
<given-names>A.</given-names>
<surname>Montaruli</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Castelli</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Mul&#x000e8;</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Biological Rhythm and Chronotype: New Perspectives in Health</article-title>,&#x0201d; <source>Biomolecules</source>
<volume>11</volume>, no. <issue>4</issue> (<year>2021</year>): <elocation-id>487</elocation-id>, <pub-id pub-id-type="doi">10.3390/biom11040487</pub-id>.<pub-id pub-id-type="pmid">33804974</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="osp470064-cit-0036">
<string-name>
<given-names>V.</given-names>
<surname>Lyssenko</surname>
</string-name>, <string-name>
<given-names>C. L. F.</given-names>
<surname>Nagorny</surname>
</string-name>, <string-name>
<given-names>M. R.</given-names>
<surname>Erdos</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A Common Variant in the Melatonin Receptor Gene (MTNR1B) Is Associated With Increased Risk of Future Type 2 Diabetes and Impaired Early Insulin Secretion</article-title>,&#x0201d; <source>Nature Genetics</source>
<volume>41</volume>, no. <issue>1</issue> (<year>2009</year>): <fpage>82</fpage>&#x02013;<lpage>88</lpage>, <pub-id pub-id-type="doi">10.1038/ng.288</pub-id>.<pub-id pub-id-type="pmid">19060908</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="osp470064-cit-0037">
<string-name>
<given-names>M. D.</given-names>
<surname>Jensen</surname>
</string-name> and <string-name>
<given-names>S.</given-names>
<surname>Nielson</surname>
</string-name>, &#x0201c;<article-title>Insulin Dose Response Analysis of Free Fatty Acid Kinetics</article-title>,&#x0201d; <source>Metabolism</source>
<volume>56</volume>, no. <issue>1</issue> (<year>2007</year>): <fpage>68</fpage>&#x02013;<lpage>76</lpage>, <pub-id pub-id-type="doi">10.1016/j.metabol.2006.08.022</pub-id>.<pub-id pub-id-type="pmid">17161228</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="osp470064-cit-0038">
<string-name>
<given-names>M. A.</given-names>
<surname>Abdul&#x02010;Ghani</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Matsuda</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Bala</surname>
</string-name>, and <string-name>
<given-names>R. A.</given-names>
<surname>DeFronzo</surname>
</string-name>, &#x0201c;<article-title>Muscle and Liver Insulin Resistance Indexes Derived From the Oral Glucose Tolerance Test</article-title>,&#x0201d; <source>Diabetes</source>
<volume>30</volume>, no. <issue>1</issue> (<year>2007</year>): <fpage>89</fpage>&#x02013;<lpage>94</lpage>, <pub-id pub-id-type="doi">10.2337/dc06-1519</pub-id>.</mixed-citation></ref><ref id="osp470064-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="osp470064-cit-0039">
<string-name>
<given-names>K.</given-names>
<surname>Vollmer</surname>
</string-name>, <string-name>
<given-names>J. J.</given-names>
<surname>Holst</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Baller</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance</article-title>,&#x0201d; <source>Diabetes</source>
<volume>57</volume>, no. <issue>3</issue> (<year>2008</year>): <fpage>678</fpage>&#x02013;<lpage>687</lpage>, <pub-id pub-id-type="doi">10.2337/db07-1124</pub-id>.<pub-id pub-id-type="pmid">18057091</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="osp470064-cit-0040">
<string-name>
<given-names>N.</given-names>
<surname>Murao</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Yokoi</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Honda</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Essential Roles of Aspartate Aminotransferase 1 and Vesicular Glutamate Transporters in &#x003b2;&#x02010;cell Glutamate Signaling for Incretin&#x02010;Induced Insulin Secretion</article-title>,&#x0201d; <source>PLoS One</source>
<volume>12</volume>, no. <issue>11</issue> (<year>2017</year>): <elocation-id>e0187213</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0187213</pub-id>.<pub-id pub-id-type="pmid">29091932</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="osp470064-cit-0041">
<string-name>
<given-names>F.</given-names>
<surname>Hadizadeh</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Faghihimani</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Adibi</surname>
</string-name>, &#x0201c;<article-title>Nonalcoholic Fatty Liver Disease: Diagnostic Biomarkers</article-title>,&#x0201d; <source>World Journal of Gastrointestinal Pathophysiology</source>
<volume>8</volume>, no. <issue>2</issue> (<year>2017</year>): <fpage>11</fpage>&#x02013;<lpage>26</lpage>, <pub-id pub-id-type="doi">10.4291/wjgp.v8.i2.11</pub-id>.<pub-id pub-id-type="pmid">28573064</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="osp470064-cit-0042">
<string-name>
<given-names>J. M.</given-names>
<surname>Rytka</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Wueest</surname>
</string-name>, <string-name>
<given-names>E. J.</given-names>
<surname>Schoenle</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Konrad</surname>
</string-name>, &#x0201c;<article-title>The Portal Theory Supported by Venous Drainage&#x02013;Selective Fat Transplantation</article-title>,&#x0201d; <source>Diabetes</source>
<volume>60</volume>, no. <issue>1</issue> (<year>2011</year>): <fpage>56</fpage>&#x02013;<lpage>63</lpage>, <pub-id pub-id-type="doi">10.2337/db10-0697</pub-id>.<pub-id pub-id-type="pmid">20956499</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="osp470064-cit-0043">
<string-name>
<given-names>M. A.</given-names>
<surname>Esani</surname>
</string-name>, &#x0201c;<article-title>The Physiological Sources of, Clinical Significance of, and Laboratory&#x02010;Testing Methods for Determining Enzyme Levels</article-title>,&#x0201d; <source>Laboratory Medicine</source>
<volume>45</volume>, no. <issue>1</issue> (<year>2014</year>): <fpage>e16</fpage>&#x02013;<lpage>e18</lpage>, <pub-id pub-id-type="doi">10.1309/LMBR83WM3GNJEDLS</pub-id>.</mixed-citation></ref><ref id="osp470064-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="osp470064-cit-0044">
<string-name>
<given-names>S.</given-names>
<surname>Minato&#x02010;Inokawa</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Tsuboi&#x02010;Kaji</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Honda</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Associations of Alanine Aminotransferase/Aspartate Aminotransferase With Insulin Resistance and &#x003b2;&#x02010;cell Function in Women</article-title>,&#x0201d; <source>Scientific Reports</source>
<volume>13</volume>, no. <issue>1</issue> (<year>2023</year>): <elocation-id>7853</elocation-id>, <pub-id pub-id-type="doi">10.1038/s41598-023-35001-1</pub-id>.<pub-id pub-id-type="pmid">37188859</pub-id>
</mixed-citation></ref><ref id="osp470064-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="osp470064-cit-0045">
<string-name>
<given-names>E. M.</given-names>
<surname>Heiston</surname>
</string-name>, <string-name>
<given-names>N. Z. M.</given-names>
<surname>Eichner</surname>
</string-name>, <string-name>
<given-names>N. M.</given-names>
<surname>Gilbertson</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Two Weeks of Exercise Training Intensity on Appetite Regulation in Obese Adults With Prediabetes</article-title>,&#x0201d; <source>Journal of Applied Physiology</source>
<volume>126</volume>, no. <issue>3</issue> (<year>2019</year>): <fpage>746</fpage>&#x02013;<lpage>754</lpage>, <pub-id pub-id-type="doi">10.1152/japplphysiol.00655.2018</pub-id>.<pub-id pub-id-type="pmid">30629474</pub-id>
</mixed-citation></ref></ref-list></back></article>